Gilead Sciences Inc. (GILD) Financial Analysis and Rating

Comparison Analysis Based on SEC Data

Company Name Gilead Sciences Inc.
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances
Revenue in 2025 $29,443 million (ranked #13 out of 508 companies in the industry)
Assets as of 12/31/2025 $59,023 million (ranked #11)
Market Cap $180,816 million (Sep 9, 2026)
Analyzed report 12/31/2024 (filed 2/28/2025)

Year:
20242025

Financial Position and Performance
Annual | Quarterly

Compared with 2024 industry ratios Change during the year

worse
unchanged
Compared with all listed companies

worse

Compare with a competitor

Financial Ratios Benchmarking

Financial Ratio Comparison of company ratios for 2024
with industry ratios
(28 - Chemicals And Allied Products) 		with all listed companies
Solvency Ratios
Debt ratio 
0.67
0.48
0.67
0.61
Debt-to-equity ratio 
2.07
0.67
2.07
1.35
Interest coverage ratio 
1.71
-4.13
1.71
2.45
Liquidity Ratios
Current Ratio 
1.60
3.20
1.60
1.78
Quick Ratio 
0.50
1.84
0.50
1.06
Cash Ratio 
0.13
1.81
0.13
0.59
Profitability Ratios
Profit margin 
1.7%
-108.7%
1.7%
3%
ROE (Return on equity), after tax 
2.3%
-36.2%
2.3%
5.1%
ROA (Return on assets) 
0.8%
-25.1%
0.8%
0.9%
Activity Ratios
Asset turnover (days) 
771
1274
771
776
Receivables turnover (days) 
58
60
58
48
Resulting score -0,2 -1,0

Year:
20242025

Additional Ratios (not used in score calculation)

Financial Ratio Comparison of company ratios for 2024
with industry ratios
(28 - Chemicals And Allied Products) 		with all listed companies
Profitability Ratios
Gross margin 
78.3%
54.8%
78.3%
43.6%
Operating margin (Return on sales) 
5.8%
-21.6%
5.8%
5.1%
Activity Ratios
Inventory turnover (days) 
102
135
102
88
EBIT  $1,667M
EBITDA  $4,434M
Price Ratios
Dividend Payout Ratio 
8.15
0.33
8.15
0.30
Earnings per Share (basic)